Alzheimer’s & Dementia Care
-
June Marks Critical Period for Alzheimer’s and Brain Awareness, Highlighting Urgent Need for Research and Action
June has once again been designated as Alzheimer’s & Brain Awareness Month (ABAM), a crucial period orchestrated by the Alzheimer’s…
Read More » -
FDA Reviews Expanded Approval for Subcutaneous Leqembi Iqlik, Offering At-Home Treatment from Initiation
The U.S. Food and Drug Administration (FDA) is currently reviewing a supplemental Biologics License Application (sBLA) submitted by Biogen and…
Read More » -
Researchers Advocate for Expanded Studies into Lymphovenous Anastomosis as a Novel Therapeutic Strategy for Alzheimer’s Disease
A compelling call for expanded research into lymphovenous anastomosis (LVA), a surgical procedure designed to enhance the clearance of molecular…
Read More » -
Anavex Life Sciences Reports Sustained Long-Term Benefits of Oral Blarcamesine in Early Alzheimer’s Disease Over Nearly Three Years
Copenhagen, Denmark – Anavex Life Sciences, a biopharmaceutical company focused on central nervous system disorders, has announced that the therapeutic…
Read More » -
FDA Approves Auvelity, a First-in-Class Non-Antipsychotic Treatment for Agitation in Alzheimer’s Disease
The U.S. Food and Drug Administration (FDA) has granted approval to Auvelity (dextromethorphan-bupropion), marking a significant advancement in the management…
Read More » -
Alzheimer’s & Brain Awareness Month Mobilizes Global Efforts to Combat Rising Dementia Crisis and Advance Research
June marks Alzheimer’s & Brain Awareness Month, a pivotal period when the Alzheimer’s Association spearheads a comprehensive array of initiatives…
Read More » -
Study reports Alzheimer’s treatment gains in long-term care
Top-line data emanating from the BEACON study, a real-world observational investigation, indicate that Zunveyl (benzgalantamine) was linked to significant provider-reported…
Read More » -
Real-World BEACON Study Highlights Zunveyl’s Potential in Long-Term Alzheimer’s Care with Provider-Reported Improvements.
Top-line data emerging from the BEACON study, a real-world investigation into the therapeutic performance of Zunveyl (benzgalantamine), indicate a positive…
Read More » -
Zunveyl Associated with Provider-Reported Improvements in Alzheimer’s Patients in Real-World Long-Term Care Study
Top-line data from the BEACON study, a real-world observational investigation, indicate that Zunveyl (benzgalantamine) was associated with significant provider-reported improvements…
Read More » -
Zunveyl Demonstrates Positive Provider-Reported Outcomes in Real-World Alzheimer’s Study Among Long-Term Care Patients
Provider observations with Zunveyl cannot prove cause and effect. Top-line data emerging from the BEACON study, a real-world investigation into…
Read More »
